GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Portage Biotech Inc (XCNQ:PBT.U) » Definitions » Cyclically Adjusted PB Ratio

Portage Biotech (XCNQ:PBT.U) Cyclically Adjusted PB Ratio : (As of May. 24, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Portage Biotech Cyclically Adjusted PB Ratio?

Note: If the price history is too short, we do not calculate current Cyclically Adjusted PB Ratio for this stock. All the historical data is shown as the company's primary share's data instead.

Shiller PE for Stocks: The True Measure of Stock Valuation


Portage Biotech Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Portage Biotech's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Portage Biotech Cyclically Adjusted PB Ratio Chart

Portage Biotech Annual Data
Trend Mar14 Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.82 0.75 2.33 0.50 0.22

Portage Biotech Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.39 0.22 0.25 0.15 0.13

Competitive Comparison of Portage Biotech's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Portage Biotech's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Portage Biotech's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Portage Biotech's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Portage Biotech's Cyclically Adjusted PB Ratio falls into.



Portage Biotech Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Portage Biotech's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Portage Biotech's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=2.648/129.4194*129.4194
=2.648

Current CPI (Dec. 2023) = 129.4194.

Portage Biotech Quarterly Data

Book Value per Share CPI Adj_Book
201403 1.324 99.695 1.719
201406 0.966 100.560 1.243
201409 0.876 100.428 1.129
201412 1.362 99.070 1.779
201503 1.286 99.621 1.671
201506 2.918 100.684 3.751
201509 2.538 100.392 3.272
201512 3.281 99.792 4.255
201603 4.052 100.470 5.220
201606 4.613 101.688 5.871
201609 18.011 101.861 22.884
201612 15.641 101.863 19.872
201703 22.860 102.862 28.762
201706 60.409 103.349 75.647
201709 90.040 104.136 111.901
201712 64.708 104.011 80.515
201803 3.427 105.290 4.212
201806 3.361 106.317 4.091
201809 3.288 106.507 3.995
201812 3.199 105.998 3.906
201903 9.180 107.251 11.078
201906 9.046 108.070 10.833
201909 8.942 108.329 10.683
201912 8.971 108.420 10.709
202003 8.785 108.902 10.440
202006 8.784 108.767 10.452
202009 8.461 109.815 9.971
202012 8.685 109.897 10.228
202103 8.396 111.754 9.723
202106 10.569 114.631 11.932
202109 10.522 115.734 11.766
202112 10.410 117.630 11.453
202203 10.031 121.301 10.702
202206 9.987 125.017 10.339
202209 14.767 125.227 15.261
202212 13.982 125.222 14.451
202303 6.293 127.348 6.395
202306 6.067 128.729 6.100
202309 5.600 129.860 5.581
202312 2.648 129.419 2.648

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Portage Biotech  (XCNQ:PBT.U) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Portage Biotech Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Portage Biotech's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Portage Biotech (XCNQ:PBT.U) Business Description

Traded in Other Exchanges
Address
Clarence Thomas Building, P.O. Box 4649, Tortola, Road Town, VGB, VG1110
Portage Biotech Inc is engaged in researching and developing pharmaceutical and biotech products through to clinical proof of concept with an initial focus on unmet clinical needs. It is an immune-oncology company focused on overcoming immune resistance and currently managing 10 immuno-oncology assets at various development stages. Its pipeline products include IMM-60; IMM60 + Cell Therapy; (IMM60 / NY-ESO-1) + Keytruda and others.

Portage Biotech (XCNQ:PBT.U) Headlines

No Headlines